Somatostatin (also known as growth hormone-releasing inhibitor) is a chemically synthesized 14-amino acid cyclic polypeptide that inhibits the release of pituitary hormones, with a structure identical to natural hypothalamic hormones. It is formulated as a lyophilized powder for injection and must be stored in a cool, dark place, protected from light.
Clinically, this drug is mainly used for the treatment of gastrointestinal bleeding, including acute gastric ulcer bleeding, erosive gastritis bleeding, and severe esophageal variceal bleeding. It is also used for the prevention of pancreaticobiliary and gastrointestinal fistulas, acute pancreatitis, and postoperative complications after pancreatic surgery. The administration method is continuous intravenous infusion over 24 hours, with a total daily dose of 6 mg. The course of treatment varies depending on the indication. Transient nausea, facial flushing, abdominal pain, and blood glucose fluctuations may occur during use. It is contraindicated in pregnant and lactating women. The formulation must meet the content range specified in the pharmacopoeia (labeled amount 95.0%-104.0%) and undergo multi-dimensional quality control, including amino acid ratio, pH value, and bacterial endotoxin levels.
